keyword
MENU ▼
Read by QxMD icon Read
search

estrogen aggression

keyword
https://www.readbyqxmd.com/read/28229217/foxo3-estrogen-receptor-alpha-and-androgen-receptor-impact-tumor-growth-rate-and-infiltration-of-dendritic-cell-subsets-differentially-between-male-and-female-mice
#1
Matthew G Thompson, Daniel S Peiffer, Michelle Larson, Flor Navarro, Stephanie K Watkins
Tumors evade immune recognition and destruction in many ways including the creation of an immune-suppressive tumor microenvironment (TME). Dendritic cells (DC) that infiltrate the TME are tolerogenic, and suppress effector T cells and anti-tumor activity. Previous reports demonstrated that a key regulator of tolerance in DC is the transcription factor FOXO3. Gender disparity has been studied in cancer in relation to incidence, aggressiveness, and prognosis. Few studies have touched on the importance in relation to impact on the immune system...
February 22, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28216224/targeted-proteomics-driven-verification-of-biomarker-candidates-associated-with-breast-cancer-aggressiveness
#2
Iva Procházková, Juraj Lenčo, Alena Fučíková, Jiří Dresler, Lenka Čápková, Roman Hrstka, Rudolf Nenutil, Pavel Bouchal
Breast cancer is the most common and molecularly relatively well characterized malignant disease in women, however, its progression to metastatic cancer remains lethal for 78% of patients 5years after diagnosis. Novel markers could identify the high risk patients and their verification using quantitative methods is essential to overcome genetic, inter-tumor and intra-tumor variability and translate novel findings into cancer diagnosis and treatment. We recently identified 13 proteins associated with estrogen receptor, tumor grade and lymph node status, the key factors of breast cancer aggressiveness, using untargeted proteomics...
February 16, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28209621/prominent-oncogenic-roles-of-evi1-in-breast-carcinoma
#3
Hui Wang, Thorsten Schaefer, Martina Konantz, Martin Braun, Zsuzsanna Varga, Anna M Paczulla, Selina Reich, Francis Jacob, Sven Perner, Holger Moch, Tanja Fehm, Lothar Kanz, Klaus Schulze-Osthoff, Claudia Lengerke
Overexpression of the EVI1 oncogene is associated typically with aggressive myeloid leukemia, but is also detectable in breast carcinoma (BC) where its contributions are unexplored. Analyzing a tissue microarray of 608 BC patient specimens, we documented EVI1 overexpression in both estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) BC. Here we report prognostic relevance of EVI1 overexpression in triple-negative BC (TNBC) but not in the HER2-positive BC subset. In human breast cancer cells, EVI1 silencing reduced proliferation, apoptosis resistance and tumorigenicity, effects rescued by estrogen supplementation in ER+ BC cells...
February 16, 2017: Cancer Research
https://www.readbyqxmd.com/read/28196852/inpp4b-and-pten-loss-leads-to-pi-3-4-p2-accumulation-and-inhibition-of-pi3k-in-tnbc
#4
Darien E Reed, Kevan M Shokat
: Triple-negative breast cancer [TNBC, lacks expression of estrogen receptor (ER), progesterone receptor (PR) and amplification of HER2/Neu] remains one of the most aggressive subtypes, affects the youngest patients and still lacks an effective targeted therapy(1,2). Both phosphatidylinositol-3-kinase (PI3K)-α and -β contribute to oncogenesis of solid tumors, including the development of breast cancer(3). Inositol polyphosphate-4-phosphatase type II (INPP4B) catalyzes the removal of the 4'-phosphate of phosphatidylinositol-(3,4-bisphosphate (PI-3,4-P2) creating phosphatidylinositol-3-phosphate(4)...
February 14, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28192639/a-deep-learning-based-strategy-for-identifying-and-associating-mitotic-activity-with-gene-expression-derived-risk-categories-in-estrogen-receptor-positive-breast-cancers
#5
David Romo-Bucheli, Andrew Janowczyk, Hannah Gilmore, Eduardo Romero, Anant Madabhushi
The treatment and management of early stage estrogen receptor positive (ER+) breast cancer is hindered by the difficulty in identifying patients who require adjuvant chemotherapy in contrast to those that will respond to hormonal therapy. To distinguish between the more and less aggressive breast tumors, which is a fundamental criterion for the selection of an appropriate treatment plan, Oncotype DX (ODX) and other gene expression tests are typically employed. While informative, these gene expression tests are expensive, tissue destructive, and require specialized facilities...
February 13, 2017: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://www.readbyqxmd.com/read/28179588/tp53-based-interaction-analysis-identifies-cis-eqtl-variants-for-tp53bp2-fbxo28-and-fam53a-that-associate-with-survival-and-treatment-outcome-in-breast-cancer
#6
Rainer Fagerholm, Sofia Khan, Marjanka K Schmidt, Montserrat García-Closas, Päivi Heikkilä, Jani Saarela, Jonathan Beesley, Maral Jamshidi, Kristiina Aittomäki, Jianjun Liu, H Raza Ali, Irene L Andrulis, Matthias W Beckmann, Sabine Behrens, Fiona M Blows, Hermann Brenner, Jenny Chang-Claude, Fergus J Couch, Kamila Czene, Peter A Fasching, Jonine Figueroa, Giuseppe Floris, Gord Glendon, Qi Guo, Per Hall, Emily Hallberg, Ute Hamann, Bernd Holleczek, Maartje J Hooning, John L Hopper, Agnes Jager, Maria Kabisch, Renske Keeman, Veli-Matti Kosma, Diether Lambrechts, Annika Lindblom, Arto Mannermaa, Sara Margolin, Elena Provenzano, Mitul Shah, Melissa C Southey, Joe Dennis, Michael Lush, Kyriaki Michailidou, Qin Wang, Manjeet K Bolla, Alison M Dunning, Douglas F Easton, Paul D P Pharoah, Georgia Chenevix-Trench, Carl Blomqvist, Heli Nevanlinna
TP53 overexpression is indicative of somatic TP53 mutations and associates with aggressive tumors and poor prognosis in breast cancer. We utilized a two-stage SNP association study to detect variants associated with breast cancer survival in a TP53-dependent manner. Initially, a genome-wide study (n = 575 cases) was conducted to discover candidate SNPs for genotyping and validation in the Breast Cancer Association Consortium (BCAC). The SNPs were then tested for interaction with tumor TP53 status (n = 4,610) and anthracycline treatment (n = 17,828)...
February 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28178667/anti-gd2-ch14-18-cho-coated-nanoparticles-mediate-glioblastoma-gbm-specific-delivery-of-the-aromatase-inhibitor-letrozole-reducing-proliferation-migration-and-chemoresistance-in-patient-derived-gbm-tumor-cells
#7
Amanda Tivnan, Tatjana Heilinger, Joanne Ramsey, Gemma O'Connor, Jenny Pokorny, Jann Sarkaria, Brett Stringer, Bryan Day, Andrew Boyd, Ella Kim, Holger Lode, Sally-Ann Cryan, Jochen Prehn
Aromatase is a critical enzyme in the irreversible conversion of androgens to oestrogens, with inhibition used clinically in hormone-dependent malignancies. We tested the hypothesis that targeted aromatase inhibition in an aggressive brain cancer called glioblastoma (GBM) may represent a new treatment strategy. In this study, aromatase inhibition was achieved using third generation inhibitor, Letrozole, encapsulated within the core of biodegradable poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs). PLGA-NPs were conjugated to human/mouse chimeric anti-GD2 antibody ch14...
February 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28160040/acute-exposure-to-17%C3%AE-ethinylestradiol-alters-aggressive-behavior-of-mosquitofish-gambusia-affinis-toward-japanese-medaka-oryzias-latipes
#8
Hieu M Dang, Yoshihiko Inagaki, Yuta Yamauchi, Takaaki Kurihara, Cong H Vo, Yutaka Sakakibara
Behavior of the mosquitofish (Gambusia affinis) toward the Japanese medaka (Oryzias latipes) was tested under exposure to environmental 17α-ethinylestradiol (EE2), a synthetic derivative of natural estrogen, estradiol. The mosquitofish were exposed to EE2 at different concentrations-0, 0.5, 5.0, and 50.0 ng/L-for 2 days, before their behavioral changes toward the medaka were observed. Results indicate that female mosquitofish became more aggressive at the high level of EE2 (50 ng/L), in terms of how persistently they attempted to approach the medaka...
February 3, 2017: Bulletin of Environmental Contamination and Toxicology
https://www.readbyqxmd.com/read/28148541/silencing-the-roadblocks-to-effective-tnbc-treatments-by-sirna-nanoparticles
#9
Jenny G Parvani, Mark W Jackson
Over the past decade, RNA interference (RNAi) has been ubiquitously utilized to study biological function in vitro, however limitations were associated with its utility in vivo. More recently, small interfering RNA (siRNA) nanoparticles with improved biocompatibility have gained prevalence as a potential therapeutic option for the treatment of various diseases. The adaptability of siRNA nanoparticles enables the delivery of virtually any siRNA, which is especially advantageous for therapeutic applications in heterogeneous diseases that lack unifying molecular features, such as triple negative breast cancer (TNBC)...
February 1, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28144772/a-combined-opiate-agonist-and-antagonist-treatment-reduces-prolactin-secreting-pituitary-tumor-growth
#10
George Maglakelidze, Olivia Wynne, Dipak K Sarkar
Prolactin secreting pituitary adenomas (prolactinomas) is the most common pituitary tumors in humans. Animal studies have identified aggressive prolactinoma development in fetal alcohol exposed rats. We have recently identified a combination treatment of a μ opioid receptor antagonist naltrexone and a δ opioid receptor agonist D-Ala2-,N-Me-Phe4,Gly-ol Enkephalin (DPDPE) increases innate immune function. In this study, we tested whether naltrexone and DPDPE combination therapy is useful to control pituitary tumor growth...
January 31, 2017: Journal of Cell Communication and Signaling
https://www.readbyqxmd.com/read/28127872/quantitative-proteomics-of-breast-tumors-tissue-quality-assessment-to-clinical-biomarkers
#11
Yi Chen, David Britton, Elizabeth R Wood, Stephen Brantley, Anthony Magliocco, Ian Pike, John M Koomen
Liquid chromatography-selected reaction monitoring mass spectrometry (LC-SRM) is not only a proven tool for clinical chemistry, but also a versatile method to enhance the capability to quantify biomarkers for tumor biology research. As the treatment of cancer continues to evolve, the ability to assess multiple biomarkers to assign cancer phenotypes based on the genetic background and the signaling of the individual tumor becomes paramount to our ability to treat the patient. In breast cancer, the American Society of Clinical Oncology (ASCO) has defined biomarkers for patient assessment to guide selection of therapy: estrogen receptor, progesterone receptor, and the HER2/Neu receptor tyrosine kinase; therefore, these proteins were selected for LC-SRM assay development...
January 27, 2017: Proteomics
https://www.readbyqxmd.com/read/28124274/upregulation-of-the-esr1-gene-and-esr-ratio-esr1-esr2-is-associated-with-a-worse-prognosis-in-papillary-thyroid-carcinoma-the-impact-of-the-estrogen-receptor-%C3%AE-%C3%AE-expression-on-clinical-outcomes-in-papillary-thyroid-carcinoma-patients
#12
Jin Wook Yi, Su-Jin Kim, Jong Kyu Kim, Chan Yong Seong, Hyeong Won Yu, Young Jun Chai, June Young Choi, Kyu Eun Lee
BACKGROUND: A gender disparity exists with respect to the incidence of papillary thyroid cancer (PTC), suggesting that sex hormones such as estrogen play a role in PTC development and progression. In this study, we compared estrogen receptor gene expression patterns in PTCs to determine the clinical significance of estrogen gene expression in PTC. METHODS: We analyzed ESR1 and ESR2 messenger RNA expression counts using data from The Cancer Genome Atlas (TCGA). To validate the results of TCGA analysis, we analyzed microarray data (GSE 54958) from the Gene Expression Omnibus...
January 25, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28118820/primary-neuroendocrine-breast-carcinomas-are-associated-with-poor-local-control-despite-favourable-biological-profile-a-retrospective-clinical-study
#13
Nelli Roininen, Sari Takala, Kirsi-Maria Haapasaari, Arja Jukkola-Vuorinen, Johanna Mattson, Päivi Heikkilä, Peeter Karihtala
BACKGROUND: Breast carcinomas with neuroendocrine features (NEBC) are a very rare entity of mammary neoplasms, WHO classification of which has recently been revised. There are very limited data available about the clinical behaviour and treatment options of NEBC. METHODS: We collected retrospectively patients with NEBC from Oulu and Helsinki University Hospitals in 2007-2015. There were 43 NEBC cases during the period. RESULTS: The incidence of NEBC from all breast cancers varied from 0...
January 24, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28115406/genetic-variants-in-epigenetic-pathways-and-risks-of-multiple-cancers-in-the-game-on-consortium
#14
Reka Toth, Dominique Scherer, Linda E Kelemen, Angela Risch, Aditi Hazra, Yesilda Balavarca, Jean-Pierre J Issa, Victor Moreno, Rosalind A Eeles, Shuji Ogino, Xifeng Wu, Yuanqing Ye, Rayjean J Hung, Ellen L Goode, Cornelia M Ulrich
BACKGROUND: Epigenetic disturbances are crucial in cancer initiation, potentially with pleiotropic effects, and may be influenced by the genetic background. METHODS: In a subsets (ASSET) meta-analytic approach, we investigated associations of genetic variants related to epigenetic mechanisms with risks of breast, lung, colorectal, ovarian and prostate carcinomas using 51,724 cases and 52,001 controls. False-discovery-rate corrected p-values (q-values < 0.05) were considered statistically significant...
January 23, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28108260/metastatic-triple-negative-breast-cancer-is-dependent-on-sphks-s1p-signaling-for-growth-and-survival
#15
Aparna Maiti, Kazuaki Takabe, Nitai C Hait
About 40,000 American women die from metastatic breast cancer each year despite advancements in treatment. Approximately, 15% of breast cancers are triple-negative for estrogen receptor, progesterone receptor, and HER2. Triple-negative cancer is characterized by more aggressive, harder to treat with conventional approaches and having a greater possibility of recurrence. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid signaling mediator has emerged as a key regulatory molecule in breast cancer progression...
January 17, 2017: Cellular Signalling
https://www.readbyqxmd.com/read/28108161/behavioral-response-and-gene-expression-changes-in-fipronil-administered-male-japanese-quail-coturnix-japonica
#16
Samah R Khalil, Ashraf Awad, Hesham H Mohammed
Fipronil is an important member of the phenylpyrazole group of insecticides and is widely used for various crops and vegetables to control insects, thereby exposing birds, animals, and humans to fipronil. Currently, there is limited information on the effects of fipronil exposure in Japanese quail. Therefore, our aim was to assess the reproductive toxicological effects of fipronil in the Japanese quail in a 15-day gavage study and then its recovery over a period of 60 days. Fipronil-administration led to significant losses in both feed intake and body weight...
April 2017: Environmental Pollution
https://www.readbyqxmd.com/read/28101229/retrospective-analysis-of-breast-cancer-prognosis-among-young-and-older-women-in-a-brazilian-cohort-of-738-patients-1985-2002
#17
Fabiana De Lima Vazquez, Thiago Buosi Silva, René Aloísio Da Costa Vieira, Allini Mafra Da Costa, Cristovam Scapulatempo, José Humberto Tavares Guerreiro Fregnani, Edmundo Carvalho Mauad, Adhemar Longatto, Kari Juhani Syrjänen
Invasive breast cancer (BC) is infrequent among women aged ≤40 years, however, the disease outlook in these younger patients is generally worse than among older women. The present study aimed to compare socio-demographic, clinical and pathological characteristics, and their association with long-term survival, between two random cohorts of young (≤40 years) and older (50-69 years) Brazilian patients with BC. The cohort comprised of 738 randomly selected women who were diagnosed with BC at Barretos Cancer Hospital, Pio XII Foundation (Barretos, Brazil) between January 1985 and December 2002; the patients included young women (n=376) and older women (n=362)...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28079144/igf-ir-cooperates-with-er%C3%AE-to-inhibit-breast-cancer-cell-aggressiveness-by-regulating-the-expression-and-localisation-of-ecm-molecules
#18
Nikolaos A Afratis, Panagiotis Bouris, Spyros S Skandalis, Hinke A Multhaupt, John R Couchman, Achilleas D Theocharis, Nikos K Karamanos
IGF-IR is highly associated with the behaviour of breast cancer cells. In ERα-positive breast cancer, IGF-IR is present at high levels. In clinical practice, prolonged treatment with anti-estrogen agents results in resistance to the therapy with activation of alternative signaling pathways. Receptor Tyrosine Kinases, and especially IGF-IR, have crucial roles in these processes. Here, we report a nodal role of IGF-IR in the regulation of ERα-positive breast cancer cell aggressiveness and the regulation of expression levels of several extracellular matrix molecules...
January 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28076434/diabetes-and-breast-cancer-subtypes
#19
Heleen K Bronsveld, Vibeke Jensen, Pernille Vahl, Marie L De Bruin, Sten Cornelissen, Joyce Sanders, Anssi Auvinen, Jari Haukka, Morten Andersen, Peter Vestergaard, Marjanka K Schmidt
BACKGROUND: Women with diabetes have a worse survival after breast cancer diagnosis compared to women without diabetes. This may be due to a different etiological profile, leading to the development of more aggressive breast cancer subtypes. Our aim was to investigate whether insulin and non-insulin treated women with diabetes develop specific clinicopathological breast cancer subtypes compared to women without diabetes. METHODS AND FINDINGS: This cross-sectional study included randomly selected patients with invasive breast cancer diagnosed in 2000-2010...
2017: PloS One
https://www.readbyqxmd.com/read/28073843/active-estrogen-receptor-alpha-signaling-in-ovarian-cancer-models-and-clinical-specimens
#20
Courtney L Andersen, Matthew J Sikora, Michelle M Boisen, Tianzhou Ma, Alec Christie, George Tseng, Yong Seok Park, Soumya Luthra, Uma Chandran, Paul Haluska, Gina Mantia-Smaldone, Kunle Odunsi, Karen McLean, Adrian V Lee, Esther Elishaev, Robert P Edwards, Steffi Oesterreich
PURPOSE: High-grade serous ovarian cancer (HGSOC) is an aggressive disease with few available targeted therapies. Despite high expression of estrogen receptor-alpha in ~80% of HGSOC and some small but promising clinical trials of endocrine therapy, estrogen receptor-alpha has been understudied as a target in this disease. We sought to identify hormone-responsive, estrogen receptor-alpha-dependent HGSOC. EXPERIMENTAL DESIGN: We characterized endocrine response in HGSOC cells across culture conditions (2-D, 3-D, forced suspension) and in patient-derived xenograft (PDX) explants, assessing proliferation and gene expression...
January 10, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
30210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"